Blueprint Medicines Corporation (BPMC) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Cambridge, MA, United States. वर्तमान CEO हैं Kathryn Haviland.
BPMC के पास है IPO तिथि 2015-04-30, 682 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $8.36B.
Blueprint Medicines Corporation is a precision therapy company that develops targeted medicines for genomically defined cancers and blood disorders globally. The company's marketed and pipeline products include AYVAKIT and BLU-263 for systemic mastocytosis and mast cell disorders, GAVRETO for RET fusion-positive cancers, Fisogatinib for hepatocellular carcinoma, and several investigational therapies targeting EGFR mutations in non-small-cell lung cancer, as well as rare genetic disorders. Blueprint maintains strategic collaborations with leading pharmaceutical partners including Genentech, Roche, CStone Pharmaceuticals, and Zai Lab to advance its precision medicine pipeline. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company is committed to delivering transformative treatments for patients with serious diseases driven by specific genetic alterations.
